AMENDED AND RESTATED NANO-REFORMULATED COMPOUND LICENSE AGREEMENTReformulated Compound License Agreement • May 17th, 2019 • Egalet Corp • Pharmaceutical preparations • Delaware
This Amended and Restated Nano-Reformulated Compound License Agreement (this “Agreement”), dated October 30, 2018 (the “Agreement Date”), is made by and among iCeutica Inc., a Delaware corporation (“iCeutica Inc.”), its wholly-owned subsidiary iCeutica Pty Ltd., an Australian corporation (together, “iCeutica”), Iroko Pharmaceuticals, LLC, a Delaware limited liability company (“Iroko LLC”) and Iroko Properties Inc., a British Virgin Islands company (“Properties BVI” and together with Iroko LLC, “Iroko”). iCeutica and Iroko are individually referred to herein as a “Party” and collectively referred to herein as the “Parties.”
NANO-REFORMULATED COMPOUND LICENSE AGREEMENTReformulated Compound License Agreement • July 11th, 2013 • Iroko Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This is a Nano-Reformulated Compound License Agreement, dated as of December 28, 2012 (the “Effective Date”), by and among iCeutica Inc. (“iCeutica Inc.”), a Delaware corporation having an address of One Kew Place, 150 Rouse Boulevard, Philadelphia, PA, 19112, its wholly owned subsidiary iCeutica Pty Ltd (“iCeutica”) (ACN 113 244 152), an Australian corporation having an address of Unit 4, 97 Hector Street, Osborne Park, Western Australia 6016, and Iroko Pharmaceuticals Inc. (“Iroko”), a company incorporated under the laws of the British Virgin Islands having an address of Geneva Place, Waterfront Drive, PO Box 3469, Road Town, Tortola, British Virgin Islands.
